Psoriasis in pregnancy: a review (II)

Actas Dermosifiliogr. 2014 Nov;105(9):813-21. doi: 10.1016/j.ad.2013.06.005. Epub 2013 Dec 4.
[Article in English, Spanish]

Abstract

Scarce scientific evidence is available to define the precise effects that certain drugs might have on embryonic and fetal development if taken by pregnant women with psoriasis, given the ethical concerns that preclude enrolling such women in clinical trials. The little information on the use of biologics during gestation that has been published is based on retrospective and observational studies, and experience with these drugs in this context in psoriasis is still very limited. The literature seems to suggest that biologic therapy is safe during pregnancy, but there is no certainty. This detailed review of accumulated experience with biologic therapy during pregnancy relies mainly on descriptions of the management of other types of rheumatic disease, although the use of these agents in psoriasis is growing steadily.

Keywords: Agentes antifactor de necrosis tumoral alfa; Biologic therapy; Embarazo; Pregnancy; Psoriasis; Terapia biológica; Tumor necrosis factor alpha inhibitors.

Publication types

  • Review

MeSH terms

  • Abnormalities, Drug-Induced / etiology*
  • Abnormalities, Drug-Induced / prevention & control
  • Animals
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / pharmacokinetics
  • Antirheumatic Agents / therapeutic use
  • Biological Products / adverse effects*
  • Biological Products / pharmacokinetics
  • Biological Products / therapeutic use
  • Female
  • Fetus / drug effects
  • Humans
  • Infant, Newborn
  • Milk, Human / chemistry
  • Pregnancy
  • Pregnancy Complications / drug therapy*
  • Prenatal Exposure Delayed Effects
  • Psoriasis / drug therapy*
  • Risk Assessment
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antirheumatic Agents
  • Biological Products
  • Tumor Necrosis Factor-alpha